Gsa Capital Partners LLP Amylyx Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$2.71 - $19.57 $142,342 - $1.03 Million	-52,525 Reduced 39.74%	79,652 $226,000
Q4 2023 Feb 16, 2024	BUY	$12.07 - $18.46 $1.08 Million - $1.66 Million	89,742 Added 211.48%	132,177 $1.95 Million
Q3 2023 Nov 15, 2023	BUY	$18.08 - $23.45 $514,032 - $666,706	28,431 Added 203.02%	42,435 $776,000
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $123,677 - $185,220	5,895 Added 72.7%	14,004 $302,000
Q1 2023 May 12, 2023	BUY	$27.71 - $40.93 $224,700 - $331,901	8,109 New	8,109 $237,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $308M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.